Bio-Thera is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $12.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Bio-Thera's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Starjemza |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Cosentyx BAT2306 |
Novartis | Biosimilar | 2029 | Phase 3 complete | $6.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Bio-Thera's share of it.